Skip to content

Biological therapies in the systemic management of psoriasis: International Consensus Conference

Biological therapies in the systemic management of psoriasis: International Consensus Conference. British Journal of Dermatology 2004 Aug;151 Suppl 69:3-17. Proceedings of the psoriasis combination and rotation therapy conference. Other systemic treatments for psoriasis include methotrexate or cyclosporine. In an international consensus conference on the use of biological therapies in the systemic management of psoriasis, Sterry and colleagues (2004) stated that given the apparent lack of traditional end-organ toxicity (e.

Biological therapies in the systemic management of psoriasis: International Consensus Conference 2Biological therapies in the systemic management of psoriasis; International Consensus Conference. Br J Dermatol, 151 (2004), pp. 3-17. Medline. 4. D. Thaci. Cosentyx is the only biologic that can be used as first-line systemic therapy in the treatment of psoriasis and as an alternative to treatments that have significant side effects 1; all other biologics are recommended for second-line therapy 2-4. Currently, all biologic treatments for psoriasis, including anti-tumor necrosis factor therapies (anti-TNFs) and Stelara (ustekinumab) are recommended for second-line systemic therapy in Europe 2-4. Biological therapies in the systemic management of psoriasis: International Consensus Conference. Biological therapies in the systemic management of psoriasis: International Consensus Conference. Article September 2004 British Journal of Dermatology.

Biological therapies in the systemic management of psoriasis: International Consensus Conference. Br J Dermatol. 2004;151 Suppl 69:3-17. Biologic agents used in the treatment of psoriasis include the anti-TNF agents adalimumab, etanercept, and infliximab, the anti-interleukin (IL)-12/23 antibody ustekinumab, and the anti-IL-17 antibody secukinumab. Consensus conference: acitretin in combination with UVB or PUVA in the treatment of psoriasis. Safety observations in 12095 patients with psoriasis enrolled in an international registry (PSOLAR): experience with infliximab and other systemic and biologic therapies. Currently, all biologic treatments for psoriasis, including anti- tumor necrosis factor therapies (anti-TNFs) and ustekinumab are recommended for second-line systemic therapy in Europe 5 – 7. Secukinumab (at a dose of 300 mg) is the first interleukin-17A (IL-17A) inhibitor to be recommended as a first-line treatment option for psoriasis patients who require systemic therapy in Europe. Biological therapies in the systemic management of psoriasis: International Consensus Conference.

Adverse Reactions During Biological Therapy For Psoriasis: Results Of A Survey Of The Spanish Psoriasis Group

Biological therapies in the systemic management of psoriasis: International Consensus Conference 3Although non-biological therapies, including methotrexate and ciclosporin, show significant efficacy their side effect profiles have precluded their long term use for moderate to severe psoriasis. It is hoped that the introduction of new agents that are more targeted and that hold the promise of fewer side effects will cause patients and their physicians to reconsider systemic treatment and, as a consequence, stimulate other patients to reconsider treatment for psoriasis. Presented at the International Psoriasis Society Meeting, June 2003, New York. Consensus conference: acitretin in combination with UVB or PUVA in the treatment of psoriasis. Psoriasis requires long-term maintenance and strict adherence to treatment regimens during both remission and flare-up periods; however, this concept is often not internalized in patients. Topical treatment, phototherapy, and non-biologic systemic treatments have various limitations to consider when constructing treatment plans (Table 1). Large disease-based registries such as psoriasis enrolled in an international registry (PSOLAR) allow long-term observation of biologic therapy to better understand and characterize treatment impact. McClelland P. Consensus conference: acitretin in combination with UVB or PUVA in the treatment of psoriasis. Mehlis S, Gordon KB: From laboratory to clinic: Rationale for biologic therapy. 5Sterry, W, Barker, J, Boehncke, WH et al. Biological therapies in the systemic management of psoriasis: International Consensus Conference. Br J Dermatol. The biologic therapy should be kept reserved for severe psoriasis only. Biological therapies in the systemic management of psoriasis: International Consensus Conference. Biological therapies in the systemic management of psoriasis: International Consensus Conference. Br J Dermatol. 2004;151 Suppl 69:3-17.

Login